We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Adagene Inc. Sponsored ADR (ADAG - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Adagene Inc. Sponsored ADR is a member of the Medical sector. This group includes 972 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Adagene Inc. Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ADAG's full-year earnings has moved 7.2% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that ADAG has returned about 2% since the start of the calendar year. At the same time, Medical stocks have lost an average of 2.3%. This means that Adagene Inc. Sponsored ADR is outperforming the sector as a whole this year.
Bayer Aktiengesellschaft (BAYRY - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 65.4%.
In Bayer Aktiengesellschaft's case, the consensus EPS estimate for the current year increased 9.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adagene Inc. Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 483 individual stocks and currently sits at #88 in the Zacks Industry Rank. This group has gained an average of 3% so far this year, so ADAG is slightly underperforming its industry in this area.
In contrast, Bayer Aktiengesellschaft falls under the Large Cap Pharmaceuticals industry. Currently, this industry has 10 stocks and is ranked #102. Since the beginning of the year, the industry has moved -0.4%.
Adagene Inc. Sponsored ADR and Bayer Aktiengesellschaft could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Adagene Inc. Sponsored ADR (ADAG - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Adagene Inc. Sponsored ADR is a member of the Medical sector. This group includes 972 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Adagene Inc. Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ADAG's full-year earnings has moved 7.2% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that ADAG has returned about 2% since the start of the calendar year. At the same time, Medical stocks have lost an average of 2.3%. This means that Adagene Inc. Sponsored ADR is outperforming the sector as a whole this year.
Bayer Aktiengesellschaft (BAYRY - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 65.4%.
In Bayer Aktiengesellschaft's case, the consensus EPS estimate for the current year increased 9.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adagene Inc. Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 483 individual stocks and currently sits at #88 in the Zacks Industry Rank. This group has gained an average of 3% so far this year, so ADAG is slightly underperforming its industry in this area.
In contrast, Bayer Aktiengesellschaft falls under the Large Cap Pharmaceuticals industry. Currently, this industry has 10 stocks and is ranked #102. Since the beginning of the year, the industry has moved -0.4%.
Adagene Inc. Sponsored ADR and Bayer Aktiengesellschaft could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.